Overview
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H receptors, α-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use).
Background
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H receptors, α-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use).
Indication
For relief of symptoms in various depressive syndromes, especially endogenous depression. It has also been used to manage chronic peripheral neuropathic pain, as a second line agent for the management of anxiety disorders (e.g. panic disorder, generalized anxiety disorder), and as a second or third line agent in the ADHD management.
Associated Conditions
- Anorexia Nervosa (AN)
- Bulimia Nervosa
- Chronic Pain
- Depression
- Diabetic Neuropathies
- Insomnia
- Irritable Bowel Syndrome (IBS)
- Neuropathic Pain
- Panic Disorder
- Postherpetic Neuralgia
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2018/11/01 | Phase 4 | Terminated | |||
2018/06/07 | Phase 4 | Recruiting | |||
2015/05/06 | Phase 2 | Completed | |||
2015/04/28 | Phase 2 | Completed | |||
2014/10/24 | Phase 1 | Completed | |||
2013/07/15 | Not Applicable | Terminated | |||
2012/11/01 | Phase 2 | Terminated | Joel Neal | ||
2011/11/23 | Phase 1 | Completed | |||
2011/08/11 | Phase 1 | Completed | |||
2011/05/24 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Ingenus Pharmaceuticals, LLC | 50742-114 | ORAL | 50 mg in 1 1 | 6/22/2023 | |
Alembic Pharmaceuticals Inc. | 62332-320 | ORAL | 150 mg in 1 1 | 10/12/2021 | |
Bryant Ranch Prepack | 71335-1021 | ORAL | 10 mg in 1 1 | 11/9/2021 | |
Alembic Pharmaceuticals Inc. | 62332-316 | ORAL | 25 mg in 1 1 | 10/12/2021 | |
Alembic Pharmaceuticals Inc. | 62332-319 | ORAL | 100 mg in 1 1 | 10/12/2021 | |
Actavis Pharma, Inc. | 45963-344 | ORAL | 75 mg in 1 1 | 12/26/2023 | |
Amneal Pharmaceuticals NY LLC | 69238-1055 | ORAL | 25 mg in 1 1 | 3/15/2023 | |
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-583 | ORAL | 150 mg in 1 1 | 11/9/2021 | |
INDICUS PHARMA LLC | 24724-071 | ORAL | 100 mg in 1 1 | 7/21/2016 | |
Alembic Pharmaceuticals Inc. | 62332-315 | ORAL | 10 mg in 1 1 | 10/12/2021 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |